Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026)
Kyverna Therapeutics posted quarterly Income from Continuing Operations of 39707000.0 for Q1 2026, up 10.99% year-on-year from 35776320.59 in Q1 2025, and down 4.99% on a QoQ basis from 37821000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Income from Continuing Operations data on file, last reported at 39707000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 10.99% year-over-year to 39707000.0; the trailing twelve-month figure through Mar 2026 stood at 156322000.0 (down 7.56% YoY), and the FY2025 full-year result was 161222000.0, down 26.56% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 39707000.0, down from 37821000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11140000.0 in Q1 2023 and bottomed at 44608000.0 in Q1 2025.
- The 4-year median for Income from Continuing Operations is 34447000.0 (2024), against an average of 29894461.54.
- The widest annual swing landed in 2024, when Income from Continuing Operations sank 139.38%; it then advanced 10.99% in 2026.
- A 4-year view of Income from Continuing Operations shows it stood at 20635000.0 in 2023, then sank by 81.7% to 37493000.0 in 2024, then dropped by 0.87% to 37821000.0 in 2025, then fell by 4.99% to 39707000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 39707000.0 (Q1 2026), 37821000.0 (Q4 2025), and 36734000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -39.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.71 Mn |
| Dec 31, 2025 | -37.82 Mn |
| Sep 30, 2025 | -36.73 Mn |
| Jun 30, 2025 | -42.06 Mn |
| Mar 31, 2025 | -44.61 Mn |
| Dec 31, 2024 | -37.49 Mn |
| Sep 30, 2024 | -34.45 Mn |
| Jun 30, 2024 | -28.78 Mn |
| Mar 31, 2024 | -26.67 Mn |
| Dec 31, 2023 | -20.64 Mn |
| Sep 30, 2023 | -15.45 Mn |
| Jun 30, 2023 | -13.08 Mn |
| Mar 31, 2023 | -11.14 Mn |